Skip to NavigationSkip to content

NHS patients to receive AbbVie's Skyrizi for plaque psoriasis following NICE recommendation

Published on 21/08/19 at 12:05pm

AbbVie’s Skyrizi (risankizumab) has been awarded a positive recommendation from UK drug watchdog NICE, meaning that the IL-23 inhibitor will now be made available to eligible patients across England and Wales for the treatment of plaque psoriasis in those who have failed conventional systemic therapies, the company has announced.

The drug, which is jointly developed along with Boehringer Ingelheim, navigated the organisation’s Fast Track pathway; the institute's decision will now be implemented within 30 days as opposed to the traditional 90.

The ruling was based on data which showed Skyrizi demonstrated high rates of skin clearance after 16 weeks of use, which was maintained through 52 weeks of treatment.

Around 820,000 people are affected by the chronic condition plaque psoriasis in the UK.

The decision means that eligible patients can access the therapy almost two months earlier than via the conventional pathway.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches